Biocon Biologics and Viatris launch first-ever interchangeable biosimilars SEMGLEE and Insulin Glargine injection in US, Health News, ET HealthWorld

Bengaluru : Biocon Biologics Ltd, a subsidiary of Biocon and Viatris Inc, announced the US launch of interchangeable biosimilars SEMGLEE (insulin glargine-yfgn) injection, a branded product, and Insulin Glargine (insulin glargine-yfgn) injection, an unbranded product, to help control high blood sugar in adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

In a statement Biocon Biologics Ltd informed that both biosimilar products are available in vial and prefilled pen presentations and are interchangeable for the reference brand, LANTUSĀ® (insulin glargine), allowing for substitution at the pharmacy counter.

Commenting on the launch of both biosimilar products in US, Shreehas Tambe, Deputy CEO, Biocon Biologics said, “The launch of our interchangeable biosimilar insulin glargine in the U.S. by our partner Viatris, is in line with our aspiration to provide our biosimilar insulins to ‘one in five’ insulin dependent people with diabetes, globally. This is indeed a landmark event and along with the recent formulary listings, we believe it will allow us to improve accessibility, availability and adoption of biosimilars in the U.S. for the benefit of patients and the overall healthcare system.”

SEMGLEE (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn), co-developed by Viatris and Biocon Biologics, are now available in the U.S. market. The currently marketed non-interchangeable SEMGLEE (insulin glargine) is anticipated to be phased out by the end of the 2021 calendar year.

Speaking about the launch, Jose Cotarelo, Viatris Head of North America, said: “We are extremely proud to stay true to that promise by bringing to millions of people with diabetes these interchangeable insulin biosimilar treatment options. We are pleased to also offer a broad range of options to help patients, which are intended to maximize access to these important medicines, regardless of financial circumstances, insurance or channel.”

To further expand access to insulins, Viatris has established a range of options to help patients, which includes, a patient assistance program, which may provide free medicine to eligible patients with demonstrated financial need. Copay Program offered for eligible commercially-insured patients, which may help reduce out-of-pocket expenses on prescriptions to as little as $0 per 30-day supply. Voucher for new patients to receive five free 3 ml pens or two free 10 ml vials. Also, cash-pay programs to reduce out-of-pocket costs when paying at the pharmacy counter.

Source link